172 related articles for article (PubMed ID: 27861143)
21. [Studies on nuclear DNA content in testicular germ cell tumors using flow cytometry].
Kashiwagi A
Hokkaido Igaku Zasshi; 1992 Nov; 67(6):801-14. PubMed ID: 1336479
[TBL] [Abstract][Full Text] [Related]
22. Surveillance of postchemotherapy subcentimeter residual retroperitoneal mass in metastatic nonseminomatous germ cell tumor: Does how you measure matter?
Cotner CE; Hilton S; Mamtani R; Guzzo T; Vaughn DJ
Urol Oncol; 2021 Feb; 39(2):136.e11-136.e17. PubMed ID: 33308971
[TBL] [Abstract][Full Text] [Related]
23. Resection of Residual Masses After Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumors in Adolescents and Adults.
Gilligan TD
J Clin Oncol; 2023 Aug; 41(23):3899-3904. PubMed ID: 37410968
[No Abstract] [Full Text] [Related]
24. Genomic evolution and chemoresistance in germ-cell tumours.
Taylor-Weiner A; Zack T; O'Donnell E; Guerriero JL; Bernard B; Reddy A; Han GC; AlDubayan S; Amin-Mansour A; Schumacher SE; Litchfield K; Turnbull C; Gabriel S; Beroukhim R; Getz G; Carter SL; Hirsch MS; Letai A; Sweeney C; Van Allen EM
Nature; 2016 Nov; 540(7631):114-118. PubMed ID: 27905446
[TBL] [Abstract][Full Text] [Related]
25. Relationship between primary and metastatic testicular germ cell tumors: a clinicopathologic analysis of 100 cases.
Tarrant WP; Czerniak BA; Guo CC
Hum Pathol; 2013 Oct; 44(10):2220-6. PubMed ID: 23856516
[TBL] [Abstract][Full Text] [Related]
26. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
[TBL] [Abstract][Full Text] [Related]
27. Nodule Size After Chemotherapy and Primary-Tumor Teratoma Components Predict Malignancy of Residual Pulmonary Nodules in Metastatic Nonseminomatous Germ Cell Tumor.
Toyoshima Y; Hara T; Matsui Y; Nagumo Y; Maejima A; Shinoda Y; Komiyama M; Watanabe SI; Fujimoto H
Ann Surg Oncol; 2018 Nov; 25(12):3668-3675. PubMed ID: 30191415
[TBL] [Abstract][Full Text] [Related]
28. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
[TBL] [Abstract][Full Text] [Related]
29. DNA methyltransferase-3 like protein expression in various histological types of testicular germ cell tumor.
Matsuoka T; Kawai K; Ando S; Sugita S; Kandori S; Kojima T; Miyazaki J; Nishiyama H
Jpn J Clin Oncol; 2016 May; 46(5):475-81. PubMed ID: 26917601
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology of male seminomatous and nonseminomatous germ cell tumors and response to first-line chemotherapy from a tertiary cancer center in India.
Joshi A; Zanwar S; Shetty N; Patil V; Noronha V; Bakshi G; Prakash G; Menon S; Prabhash K
Indian J Cancer; 2016; 53(2):313-316. PubMed ID: 28071636
[TBL] [Abstract][Full Text] [Related]
31. Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors.
Li X; Guo S; Wu Z; Dong P; Li Y; Zhang Z; Yao K; Han H; Qin Z; Zhou F; Liu Z
World J Urol; 2015 Sep; 33(9):1351-7. PubMed ID: 25471669
[TBL] [Abstract][Full Text] [Related]
32. The pathology of late recurrence of testicular germ cell tumors.
Michael H; Lucia J; Foster RS; Ulbright TM
Am J Surg Pathol; 2000 Feb; 24(2):257-73. PubMed ID: 10680894
[TBL] [Abstract][Full Text] [Related]
33. Differentiation of testicular seminoma and nonseminomatous germ cell tumor on magnetic resonance imaging.
Liu R; Lei Z; Li A; Jiang Y; Ji J
Medicine (Baltimore); 2019 Nov; 98(45):e17937. PubMed ID: 31702681
[TBL] [Abstract][Full Text] [Related]
34. Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy.
Necchi A; Bratslavsky G; Corona RJ; Chung JH; Millis SZ; Elvin JA; Vergilio JA; Suh J; Ramkissoon S; Severson E; Daniel S; Killian JK; Ali SM; Schrock AB; Reddy P; Miller VA; Welsh A; Gay LM; Ross JS
Eur Urol Focus; 2020 Jan; 6(1):122-130. PubMed ID: 30025711
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase II alpha expression in testicular germ cell tumors.
Dimov ND; Zynger DL; Luan C; Kozlowski JM; Yang XJ
Urology; 2007 May; 69(5):955-61. PubMed ID: 17482942
[TBL] [Abstract][Full Text] [Related]
36. Long-term clinical outcome in patients with stage-I nonseminomatous germ cell cancer. A critical review of own treatment modalities in a retrospective study.
Seseke S; Bierwirth S; Strauss A; Ringert RH; Seseke F
Int Braz J Urol; 2008; 34(6):715-22; discussion 723-4. PubMed ID: 19111076
[TBL] [Abstract][Full Text] [Related]
37. Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features.
Toner GC; Geller NL; Lin SY; Bosl GJ
Cancer; 1991 Apr; 67(8):2049-57. PubMed ID: 1848473
[TBL] [Abstract][Full Text] [Related]
38. Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era.
Yuasa T; Inoshita N; Tanaka H; Urakami S; Yamamoto S; Fujii Y; Masuda H; Fukui I; Ishikawa Y; Yonese J
Int J Clin Oncol; 2015 Dec; 20(6):1198-202. PubMed ID: 25893862
[TBL] [Abstract][Full Text] [Related]
39. Genomic characterization of testis cancer: association of alterations with outcome of clinical stage 1 mixed germ cell nonseminomatous germ cell tumor of the testis.
Mohamed GH; Gelfond JA; Nicolas MM; Brand TC; Sarvis JA; Leach RJ; Johnson-Pais TL
Urology; 2012 Aug; 80(2):485.e1-5. PubMed ID: 22503760
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome of robot-assisted residual mass resection in metastatic nonseminomatous germ cell tumor.
Blok JM; van der Poel HG; Kerst JM; Bex A; Brouwer OR; Bosch JLHR; Horenblas S; Meijer RP
World J Urol; 2021 Jun; 39(6):1969-1976. PubMed ID: 32955662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
